Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Cardiff Oncology, Inc. (CRDF : NSDQ)
 
 • Company Description   
Cardiff Oncology Inc. is a clinical-stage biotechnology company. It engages in developing treatment for cancer patients. The company's product pipeline consists of a Phase 1b/2 study of onvansertib in combination with FOLFIRI/Avastin(R) in KRAS-mutated metastatic colorectal cancer; a Phase 2 study of onvansertib in combination with Zytiga(R) in Zytiga-resistant metastatic castration-resistant prostate cancer; and a Phase 2 study of onvansertib in combination with decitabine in relapsed or refractory acute myeloid leukemia. Cardiff Oncology Inc., formerly known as Trovagene Inc., is based in SAN DIEGO.

Number of Employees: 23

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.28 Daily Weekly Monthly
20 Day Moving Average: 759,924 shares
Shares Outstanding: 43.31 (millions)
Market Capitalization: $55.43 (millions)
Beta: 2.04
52 Week High: $8.58
52 Week Low: $1.13
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -14.67% -3.88%
12 Week -52.06% -47.29%
Year To Date -78.70% -73.98%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
11055 FLINTKOTE AVENUE
-
SAN DIEGO,CA 92121
USA
ph: 858-952-7570
fax: -
ir@cardiffoncology.com https://cardiffoncology.com
 
 • General Corporate Information   
Officers
Mark Erlander - Chief Executive Officer
Rodney S. Markin - Chairman
James Levine - Chief Financial Officer
James O. Armitage - Director
John Brancaccio - Director

Peer Information
Cardiff Oncology, Inc. (CORR.)
Cardiff Oncology, Inc. (RSPI)
Cardiff Oncology, Inc. (CGXP)
Cardiff Oncology, Inc. (BGEN)
Cardiff Oncology, Inc. (GTBP)
Cardiff Oncology, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 14147L108
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/04/22
Share - Related Items
Shares Outstanding: 43.31
Most Recent Split Date: 2.00 (0.17:1)
Beta: 2.04
Market Capitalization: $55.43 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.25 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.05 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/04/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.43
Price/Cash Flow: -
Price / Sales: 153.55
EPS Growth
vs. Year Ago Period: -78.57%
vs. Previous Quarter: -8.70%
Sales Growth
vs. Year Ago Period: 2.78%
vs. Previous Quarter: -44.36%
ROE
03/31/22 - -25.12
12/31/21 - -21.05
09/30/21 - -19.37
ROA
03/31/22 - -23.77
12/31/21 - -20.06
09/30/21 - -18.53
Current Ratio
03/31/22 - 20.38
12/31/21 - 22.28
09/30/21 - 27.32
Quick Ratio
03/31/22 - 20.38
12/31/21 - 22.28
09/30/21 - 27.32
Operating Margin
03/31/22 - -9,447.37
12/31/21 - -7,880.50
09/30/21 - -7,375.65
Net Margin
03/31/22 - -9,447.37
12/31/21 - -7,880.50
09/30/21 - -7,375.65
Pre-Tax Margin
03/31/22 - -9,447.37
12/31/21 - -7,880.50
09/30/21 - -7,375.65
Book Value
03/31/22 - 3.00
12/31/21 - 3.55
09/30/21 - 3.38
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©